Voyager Therapeutics, Inc. Forecast, price target & analysts
Voyager Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation
Voyager Therapeutics, Inc. Classifications & Recommendation:
Voyager Therapeutics, Inc. Price Target
| Target Price | $16.70 |
| Price | $4.01 |
| Potential |
316.46%
register free of charge
|
| Number of Estimates | 10 |
|
10 Analysts have issued a price target Voyager Therapeutics, Inc. 2026 .
The average Voyager Therapeutics, Inc. target price is $16.70.
This is
316.46%
register free of charge
$30.00
648.13%
register free of charge
$9.00
124.44%
register free of charge
|
|
| A rating was issued by 12 analysts: 12 Analysts recommend Voyager Therapeutics, Inc. to buy, 0 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Voyager Therapeutics, Inc. stock has an average upside potential 2026 of
316.46%
register free of charge
|
Sales and Margin forecast 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Revenue Million $ | 250.01 | 90.30 |
| 511.12% | 63.88% | |
| EBITDA Margin | 50.58% | -69.47% |
| 146.35% | 237.34% | |
| Net Margin | 64.79% | -55.82% |
| 140.16% | 186.15% |
12 Analysts have issued a sales forecast Voyager Therapeutics, Inc. 2024 . The average Voyager Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Voyager Therapeutics, Inc. EBITDA forecast 2024. The average Voyager Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
12 Voyager Therapeutics, Inc. Analysts have issued a net profit forecast 2024. The average Voyager Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 2.97 | -0.92 |
| 345.45% | 130.98% | |
| P/E | negative | |
| EV/Sales | negative |
12 Analysts have issued a Voyager Therapeutics, Inc. forecast for earnings per share. The average Voyager Therapeutics, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Voyager Therapeutics, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Voyager Therapeutics, Inc....
Current Voyager Therapeutics, Inc. Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Jan 27 2025 |
| Cantor Fitzgerald | Locked ➜ Locked | Locked | Jan 10 2025 |
| Citigroup | Locked ➜ Locked | Locked | Dec 02 2024 |
| Canaccord Genuity | Locked ➜ Locked | Locked | Nov 14 2024 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Nov 14 2024 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Oct 24 2024 |
| Leerink Partners | Locked ➜ Locked | Locked | Oct 16 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Jan 27 2025 |
|
Locked
Cantor Fitzgerald: Locked ➜ Locked
|
Jan 10 2025 |
|
Locked
Citigroup: Locked ➜ Locked
|
Dec 02 2024 |
|
Locked
Canaccord Genuity: Locked ➜ Locked
|
Nov 14 2024 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Nov 14 2024 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Oct 24 2024 |
|
Locked
Leerink Partners: Locked ➜ Locked
|
Oct 16 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
